Introduction
============

Thiourea and its derivatives have a broad range of applications in medicine, chemistry, industry, and agriculture. They have been found to demonstrate various biological activities such as antimicrobial,[@b1-dddt-7-883]--[@b3-dddt-7-883] anthelmintic,[@b4-dddt-7-883],[@b5-dddt-7-883] antitumor,[@b6-dddt-7-883] antiviral,[@b7-dddt-7-883] and are also suitable as insecticides,[@b8-dddt-7-883] fungicides,[@b9-dddt-7-883] herbicides,[@b10-dddt-7-883] and plant-growth regulators.[@b11-dddt-7-883] In addition, mounting evidence suggests that the moiety of thiourea also possesses analgesic and anti-inflammatory properties. A study of the structure--activity relationship of thiourea derivatives resulted in evaluating some of them as vanilloid-receptor agonists with potential analgesic and anti-inflammatory effects.[@b12-dddt-7-883] In that study, the analgesic activity, anti-inflammatory activity, and pungency of thiourea derivatives were investigated in animal models via the writhing test, ear edema assay, and eye-wiping test, respectively.[@b12-dddt-7-883]

Moreover, thiourea derivatives containing partial cyproheptadine structure have been developed and screened for antitumor and anti-inflammatory activity, and were found to show stronger anti-inflammatory activity than ibuprofen in vivo in a xylene-induced ear swelling assay in mice.[@b13-dddt-7-883] Different chemical classes of thiourea have also been synthesized and found to exhibit good anti-inflammatory activity in carrageenan-induced paw edema (CPE) in a rat model.[@b14-dddt-7-883],[@b15-dddt-7-883]

The constant medical use of nonsteroidal anti-inflammatory drugs to treat inflammation is limited since gastrointestinal adverse effects impair gastric ulcer healing.[@b16-dddt-7-883],[@b17-dddt-7-883] These gastrointestinal side effects are associated with prostaglandin E~2~ (PGE~2~) deficiency, which is caused by nonsteroidal anti-inflammatory drugs due to the inhibition of cyclooxygenase (COX) that exists in two isoenzymes: the constitutively expressed COX-1 and the inducible COX-2.[@b18-dddt-7-883] Based on the aforementioned studies and as a part of our ongoing research, the pharmacological profile of thiourea derivatives drew our interest with a view to synthesizing several new compounds belonging to the thiourea class. The newly synthesized *N*-phenylcarbamothioylbenzamides (which we called 1a--h) were screened for anti-inflammatory and ulcerogenic side-effect properties. Additionally, PGE~2~ inhibitory properties of the compounds were evaluated, since the inhibition of PGE~2~ synthesis strongly correlates with anti-inflammatory and gastric ulcerogenic properties.[@b18-dddt-7-883]

Materials and methods
=====================

General
-------

To chemically prepare the new compounds, all starter compounds used for the synthesis were variously procured from Merck & Co (Whitehouse Station, NJ, USA) and Sigma-Aldrich (St Louis, MO, USA). Freshly distilled 4-Ethylphenol was used and acetone was dried using potassium carbonate and then distilled. Dried ammonium thiocyanate treated by heating at 100°C was used in the reactions. The necessary liquid amines were dried with potassium hydroxide and afterwards distilled. Melting points were obtained with the aid of an Electrothermal 9100 capillary melting point apparatus in open capillary tubes (Bibby Scientific Ltd, Stone, UK); the values reported here are uncorrected. Elemental analysis was performed on a PerkinElmer 2400 Series II CHNS/O Analyzer (Waltham, MA, USA) and the results were within ±0.4% of the theoretical values. The Fourier-transform infrared (FT-IR) spectra of the all synthesized compounds were run on a Bruker Vertex 70 FT-IR spectrometer (Bruker Corporation, Billerica, MA, USA). Nuclear magnetic resonance (NMR) spectra were recorded employing a Varian Inova 400 instrument (Varian Medical Systems, Palo Alto, CA, USA) operating at 400.0 MHz for proton (^1^H)-NMR, 100.0 MHz for carbon-13 (^13^C)-NMR, and 376.3 MHz for fluorine-19 (^19^F)-NMR. Mass spectrometry (MS) measurements were carried out on an Agilent 6540 Ultra High Definition Q-TOF instrument (Agilent Technologies, Santa Clara, CA, USA).

Chemistry
---------

### General procedure for the preparation of compounds titled 1a--h

The synthesis of the 2-(4-ethylphenoxymethyl)benzoic acid (3) and 2-(4-ethyl-phenoxymethyl)benzoyl chloride (4) have been previously reported.[@b19-dddt-7-883],[@b20-dddt-7-883] The compounds 1a--h were prepared by adding a solution of 2-(4-ethylphenoxymethyl)-benzoyl chloride (4) (0.01 mol) in acetone (15 mL) to a solution of ammonium thiocyanate (0.01 mol) in acetone (5 mL) to correct arylisothiocyanate 2 in situ. The reaction mixture was heated under reflux for 1 hour then cooled at room temperature. A solution of primary amine (0.01 mol) in acetone (2 mL) was added to the mixture and the mixture was again heated under reflux for 1 hour. After the cooled reaction mixture was poured into 500 mL water, the respective acylthiourea was precipitated out. The solid product was purified by recrystallization from isopropanol with active carbon. The data of ^1^H-NMR, ^13^C-NMR, IR, MS, and elemental analysis for titled compounds 1a-h can be found in the Supplementary materials.

Pharmacology
------------

### Animals

All experiments were performed in adult male Tuck Ordinary (TO) mice (Harlan UK Ltd, Blackthorn, UK).[@b21-dddt-7-883] Mice were group housed in the central animal facility of the College of Medicine and Health Sciences (United Arab Emirates University) on a 12-hour light--dark cycle (lights on at 6 am). Food and water were available ad libitum. Experiments were conducted in agreement with the United Arab Emirates University Institutional Animal Care and Use Committee guidelines (protocol no A7-13).

### Anti-inflammatory activity: acute CPE

Male TO mice weighing 22--25 g were randomly divided into ten groups of five animals each. Freshly prepared 1% carrageenan in dimethyl sulfoxide (DMSO; 0.01 mL) was injected in the plantar site of the right hind paw of each mouse to induce acute inflammation. The first group remained the placebo control groups and received DMSO (1.5%) only, while the second group received the reference drug indomethacin (0.028 mmol/kg).[@b22-dddt-7-883] The remaining eight groups received test compounds 1a--h (0.028 mmol/kg, orally) dissolved in DMSO (1.5%) before induction of acute inflammation. The control and test compounds were administered orally by intubation gauge 1 hour before carrageenan injection. Right hind paw thicknesses were measured before and 3 hours after induction of inflammation by a vernier caliper to estimate the anti-edematous effects of the reference drug indomethacin and test compounds 1a--h. Percent inhibition of test compounds was calculated according to the following equation:
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in which "n" and "n′" indicate the difference in thickness between the first and second measurements of hind paws in the placebo control and test groups, respectively[@b23-dddt-7-883]--[@b27-dddt-7-883] The results were expressed as mean ± standard error of the mean, and the significant difference between groups was tested by using one-way analysis of variance followed by Tukey's honestly significant difference test at *P* \< 0.05.

### Ulcerogenicity

Male TO mice weighing 22--25 g were divided into five groups of five animals each. The animals were fasted 18 hours before drug administration. The reference compound indomethacin (0.028 mmol/kg) and the test compounds 1a, 1e, and 1h (0.028 mmol/kg) were suspended in saline solution with the aid of few drops of Tween®80 (Sigma Aldrich) and were administered orally for 3 successive days (single dose/day) to the fasted animals. The placebo control group was given saline with few drops of Tween 80. Four hours after the last dose, the animals were sacrificed and the stomachs were examined for the presence of lesions and erosions. The degree of ulcerogenicity was expressed in terms of: average number of ulcers per stomach, percentage incidence of ulcers, and ulcer index.[@b28-dddt-7-883]

### Measurement of PGE~2~ level

PGE2 level measurement was undertaken using the previously described 6-day-old air-pouch standard method in mice.[@b29-dddt-7-883]--[@b31-dddt-7-883] Male TO mice weighing 22--25 g were divided into five groups of five animals each. The air pouch was induced as follows: on the first day of the experiment, 5 mL of air was injected subcutaneously in the back of each animal. Three days later, the air pouch was reinforced with 2.5 mL of air. Then, on Day 6, and before injecting the pouch with carrageenan (1 mL of 1% solution in saline), three groups of animals were pretreated orally with test compounds 1a, 1e, and 1h at a dose of 0.028 mmol/kg body weight, the positive control group was pretreated with the reference drug indomethacin (0.028 mmol/kg) suspended in saline solution with the aid of few drops of Tween 80, and the placebo control group was pretreated with sterile saline. All injections were conducted under light ether anesthesia. Then, 1 hour after the carrageenan injection, animals were lightly anaesthetized with ether and the contents of the pouch were aspirated using a Pasteur pipette and transferred into graduated plastic tubes kept in ice. The bulk of the exudate was frozen and stored at −20°C until required for PGE~2~ assay. PGE~2~ was measured using an enzyme-linked immunosorbent assay (ELISA) technique using a PGE~2~ assay kit (Prostaglandin E~2~ EIA Kit-Monoclonal, Cayman Chemical Item Number: 514010; Cayman Chemical Company, Ann Arbor, MI, USA) according to the manufacturer's specifications. Data were collected checked and revised. Quantitative variables from normal distribution were expressed as means ± standard error of the mean. The significant difference between groups was tested using one-way analysis of variance followed by Tukey's honestly significant difference test at *P* \< 0.05.

### Acute toxicity

The acute toxicity of the most promising compounds (1e and 1h) was determined using standard methods.[@b32-dddt-7-883] Male TO mice weighing 22--25 g were divided into three groups of six mice each. The test compounds, which were dissolved in DMSO (1.5%), were injected intraperitoneally at a dose of 60 mg/kg in the first group, 120 mg/kg in the second group, and 150 mg/kg in the third group. Toxic signs and the mortality rate in each group were recorded 48 hours after drug administration.

Results
=======

Chemistry
---------

In the present study, new 2-((4-ethylphenoxy)methyl)-*N*-(substituted-phenylcarbamothioyl) benzamides (1a-h) were synthesized by allowing 2-((4-ethylphenoxy)methyl)benzoyl isothiocyanate (2), as the key intermediate, to react with variously substituted primary aromatic amines in a 1:1 molar ratio. The new compounds were synthesized by a series of reactions as shown in [Figure 1](#f1-dddt-7-883){ref-type="fig"}.

Pharmacology
------------

The results obtained from the CPE test indicate that 1a and 1d-h exhibited significantly higher anti-inflammatory activity (23.85%--61.45%) compared with the reference drug indomethacin (22.43%) (*P* = 0.049 for 1a, 0.0015 for 1d, and 0.033 for 1f; *P* = 0.00067 for 1e and 0.00081 for 1h). Notably, 1e and 1h showed the most potent anti-inflammatory activity (61.45% and 51.76%, respectively). The data observed for ulcerogenic properties clearly demonstrate that ulcerogenic potentials (ulcer incidence of 20% for 1e and 1h) were lower than those of the standard drug indomethacin (ulcer incidence of 80%). In particular, compound 1e, with an ulcer index of 0.2, showed significantly reduced ulcerogenicity when compared with indomethacin (ulcer index 0.6, *P* = 0.014). Moreover, PGE~2~ inhibition was found to be highest with 1e and 1h, which were found to have PGE~2~ levels of 68.32 pg/mL and 54.15 pg/mL, respectively. Notably, the PGE~2~ inhibition of 1h was significantly different from that of the placebo control group (*P* \< 0.001) and the indomethacin group, which decreased PGE~2~ synthesis to a level of 96.13 pg/mL (*P* \< 0.05). The significant inhibition of PGE~2~ observed with 1a, 1e, and 1h (106.31 pg/mL, 68.32 pg/mL, and 54.15 pg/mL, respectively) agree with the observed ulcer incidences of 80%, 20%, and 20%, respectively.

In addition, the acute toxicity of the most promising anti-inflammatory derivatives (1e and 1h) was observed closely, and there was no morbidity or mortality in mice at a dose of up to 150 mg/kg (body weight); that is, up to tenfold of the used effective dose. Further, during the 48-hour observation period, neither physical energy levels nor food and water intake were influenced, suggesting a good safety profile of the developed compounds.

Discussion
==========

Chemistry
---------

The new *N*-phenylcarbamothioylbenzamides 1a--h were white or light yellow crystalline solids. Although soluble at room temperature in DMSO or organic solvents like acetone and chloroform, they are soluble only when heated in lower alcohols, benzene, toluene, and xylene, and absolutely insoluble in water. The chemical structures of the newly synthesized compounds 1a--h were revealed by ^1^H-NMR, ^13^C-NMR, IR, mass spectrometry, and elemental analysis spectral studies, which confirmed the proposed structures. The IR bands were given as: "w," weak; "m," medium; "s," strong; "vs," very strong. The IR spectra provide valuable information regarding the nature of functional groups. The titled compounds were characterized mainly using the N--H of amide and the thioamide group, C--H of the methyl group, C--H of the methylene group, alkyl-aryl-ether, and the C=O and C=S bands. The IR spectra showed the expected frequencies of the νN-H of the amide group (3,357--3,349 cm^−1^) and the νN-H of the thioamide group (3,178--3,117 cm^−1^). The absorption bands for the antisymmetric stretching vibrations, the νC--H of the methyl and methylene groups, appeared at 2,971--2,958 cm^−1^ and 2,918--2,934 cm^−1^, respectively. These bands are typical for aromatic compounds containing some saturated carbon. The medium-strong νC=O band appeared at 1,693--1,669 cm^−1^, which is lower than that of ordinary carbonyl absorption (1,730 cm^−1^); this may be attributed to the formation of hydrogen bonds. The IR spectra of the target compounds showed very strong characteristic absorption of the νN--H amide group in the range of 1,503--1,516 cm^−1^. These compounds also showed typical alkyl-aryl ether at 1,248--1,223 cm^−1^ for the antisymmetric vibration and 1,044--1,026 cm^−1^ for the symmetric one. The spectra showed absorption bands at 1,159--1,176 cm^−1^, which can be attributed to the νC=S stretching frequency.

The chemical structures of the developed compounds were also supported by NMR spectra. The new *N*-phenyl-carbamothioylbenzamides were dissolved in DMSO-d6 and the chemical shift values, expressed in ppm, were referenced downfield to tetramethylsilane for ^1^H-NMR and ^13^C-NMR and upfield to trichlorofluoromethane for ^19^F-NMR and the constants (J) values in Hz. The chemical shifts for hydrogen and carbon atoms were also established by gradient correlation spectroscopy, gradient heteronuclear multiple bond coherence (GHMBC), and gradient heteronuclear single quantum coherence (GHSQC) experiments. As explained in the "Chemistry" subsection of "Methods and materials," the ^1^H-NMR data are reported in the following order: chemical shifts, multiplicity, the coupling constants, number of protons and signal/atom attribution. The apparent resonance multiplicity is described as: s (singlet), d (doublet), t (triplet), q (quartet), qv (quartet), sxt (sextet), m (multiplet), dd (double doublet), td (triple doublet), and br (broad) signal. For the ^13^C-NMR data the order is: chemical shifts, the coupling constants in some cases, and signal/atom attribution (Cq). In the ^1^H-NMR spectra, the titled compounds exhibited broad signal in the ranges 12.56--11.81 ppm and 12.12--11.67 ppm, which were assigned to the NH protons. Generally, the NMR signal of NH protons for amides is observed in the range of 9--10 ppm. The low-field shift of the signal for the proton can be attributed to the de-shielding effect of the electron-withdrawing carbonyl and thiocarbonyl groups and hydrogen bonds. The ethyl group protons appear as a triplet (--CH~3~) at 2.54--2.50 ppm and as a quartet (--CH~2~--) at 1.13--1.11 ppm. ^13^C-NMR spectra showed the peaks at about δ 180.38--178.28 ppm for C=S. The carbon atom of the carbonyl group appeared at δ 169.99--170.78 ppm, due to the existence of the intramolecular hydrogen bond related to the carbonyl oxygen atom. The mass spectra of all the analyzed compounds showed the molecular ion peaks. The peak at m/z 239.1 is derived from the 2-(4-ethylphenoxymethyl)benzoyl cation.

Pharmacology
------------

The results obtained from the CPE test model indicate that, of the derivatives developed, 1e and 1h demonstrated the most potent anti-inflammatory activity (61.45% and 51.76%, respectively) when compared with reference the drug indomethacin (22.43%) (*P* \< 0.005) ([Figure 2](#f2-dddt-7-883){ref-type="fig"}). Since *N*-phenylcarbamothioylbenzamide derivatives with (*N*-2,4-dibromophenyl)-(1e) and *N*-(3-nitrophenyl)-substituent (1h) showed the most potent anti-inflammatory activity of the current series, it was surmised that modulation of the C20 position might greatly affect the anti-inflammatory activity of the compounds investigated. This was demonstrated by the anti-inflammatory results obtained, which were significantly decreased through prolongation of the C20-positioned alkyl chain to *n*-propyl or *n*-butyl in compounds 1a (26.81%), 1b (19.79%), and 1c (no anti-inflammatory activity). Importantly, our results show that anti-inflammatory activity was achieved by small-sized substitution as present in 1a (methyl moiety) with an anti-inflammatory activity of 26.81%, an activity comparable to that of the reference drug indomethacin (22.43%) (*P* \> 0.05). The same observation of decrease in anti-inflammatory activity was obtained by shifting one bromo substituent from the C20 to C21 position, as achieved by comparing compound 1e and 1f with 61.45% and 36.68%, respectively (*P* \< 0.005). An explanation for the observed activities of 1a--c and 1e--f might be the alteration in pharmacokinetic profile in accordance with the changes in the substitution pattern of the respective *N*-phenylcarbamothioylbenzamide derivative.

The ulcerogenic properties for the most active derivatives, 1e and 1h, clearly indicate that ulcerogenic potentials -- with ulcer incidence of 20% for 1e and 1h, as well as the ulcer indices of 0.20 ± 0.02 and 0.40 ± 0.12, respectively -- were significantly reduced when compared with the reference drug indomethacin, which had an ulcer incidence of 80% and ulcer index of 0.6 (*P* \< 0.05) ([Table 1](#t1-dddt-7-883){ref-type="table"}). Interestingly, the results observed for 1a, with an ulcer incidence of 80% and ulcer index of 0.50 ± 0.16, were comparable to those for the reference drug indomethacin and in agreement with the obtained moderate anti-inflammatory effect in the CPE test model (26.81%, [Table 1](#t1-dddt-7-883){ref-type="table"} and [Figure 2](#f2-dddt-7-883){ref-type="fig"}).

PGE~2~ inhibitory properties were determined for compounds 1a, 1e, and 1h, in comparison to the reference drug indomethacin. The results were in agreement with the anti-inflammatory observations. The inhibition of PGE~2~ synthesis was found to be high with 1e and 1h, which had PGE~2~ levels of 68.32 pg/mL and 54.15 pg/mL, respectively, and was significantly different from the other derivatives and indomethacin, which had a PGE~2~ level of 96.13 pg/mL (*P* \< 0.05) ([Figure 3](#f3-dddt-7-883){ref-type="fig"}).

The comparison of the chemical structures of 1e and 1h with that of known COX-2 inhibitors (celecoxib, valdecoxib, and lumiracoxib) was of interest because of their reduced ulcerogenic potential; however, there were no structural similarities to which to attribute the reduction in the ulcerogenic effects.

Conclusion
==========

The developed *N*-phenylcarbamothioylbenzamides 1a--h showed moderate to high anti-inflammatory activity in the CPE test, potent inhibition of PGE~2~, and low ulcerogenic properties. In particular, the compounds with *N*-(2,4-dibromophenyl)- and *N*-(2-nitrophenylcarbamothioyl) benzamide substitution, 1e and 1h, respectively, significantly improved in vivo anti-inflammatory potency, potently inhibited PGE~2~ synthesis, and were endowed with low ulcerogenicity, proving that the newly developed class form potential candidates for further pharmacological investigation as well as assays on appropriate cell lines to validate their intrinsic cytotoxicity.

Supplementary materials
=======================

Key to data
-----------

The new *N*-phenylcarbamothioylbenzamides were dissolved in DMSO-d6 and the chemical shift values, expressed in ppm, were referenced downfield to tetramethylsilane for 1H-NMR and ^13^C-NMR and upfield to trichlorofluoromethane for ^19^F-NMR and the constants (J) values in Hz. In the next paragraphs, the 1H-NMR data are reported in the following order: chemical shifts, multiplicity, the coupling constants, number of protons and signal/atom attribution. The apparent resonance multiplicity is described as: s (singlet), d (doublet), t (triplet), q (quartet), qv (quartet), sxt (sextet), m (multiplet), dd (double doublet), td (triple doublet), and br (broad) signal. For the ^13^C-NMR data, the order is: chemical shifts, the coupling constants in some cases, and signal/atom attribution (quaternary carbon \[Cq\]). The explanation of the notes is as follows: J, coupling constant (Hz); IR, infrared; mp, melting point; ATR, attenuated total reflectance; MS, mass spectrometry; Anal calcd elemental analysis calculated; MH+, pseudomolecular ion; S, sulfur; C, carbon; H, hydrogen; N, nitrogen; m/z, mass/charge ratio; GHMBC, gradient heteronuclear multiple bond coherence; GHSQC, gradient heteronuclear single quantum coherence; w, weak; m, medium; s, strong; vs, very strong.

2-((4-Ethylphenoxy)methyl)-N-(2,4,6-trimethylphenylcarbamothioyl)benzamide (1a)
-------------------------------------------------------------------------------

Yield 77%; mp 139°C--141°C; 1H-NMR (hexadeuteriodimethyl sulfoxide \[DMSO-d6\]): 11.81 (br s, 1H, NH), 11.67 (br s, 1H, NH), 7.62 (dd, J = 1.4 Hz, J = 7.4 Hz, 1H, H-7), 7.59 (dd, J = 1.6 Hz, J = 7.4 Hz, 1H, H-4), 7.55 (td, J = 1.4 Hz, J = 7.4 Hz, 1H, H-5), 7.47 (td, J = 1.6 Hz, J = 7.5 Hz, 1H, H-6), 7.06 (d, J = 8.6 Hz, 2H, H-11, H-13), 6.90 (d, J = 8.6 Hz, 2H, H-10, H-14), 6.89 (s, 2H, H-19, H-21), 5.25 (s, 2H, H-8), 2.50 (q, J = 7.6 Hz, 2H, H-15), 2.24 (s, 3H, H-20′), 2.07 (s, 6H, H-18′, H-22′), 1.11 (t, J = 7.6 Hz, 3H, H-15′); ^13^C-NMR (DMSO-d6): 180.38 (C-16), 170.06 (C-1), 156.28 (C-9), 136.49 (Cq), 136.23 (Cq), 135.61 (Cq), 134.69 (C-18, C-22), 133.69 (Cq), 133.50 (Cq), 130.92 (C-5), 128.81 (C-4), 128.62 (C-11, C-13), 128.51 (C-19, C-21), 128.45 (C-7), 127.89 (C-6), 114.60 (C-10, C-14), 67.61 (C-8), 27.31 (C-15), 20.53 (C-20′), 17.68 (C-18′, C-22′), 15.87 (C-15); FT-IR (solid in ATR, ν cm^−1^): 3,162 m, 3,001 w, 2,965 m, 2,924 m, 2,862 w, 1,679 m, 1,606 w, 1,506 vs, 1,381 m, 1,332 w, 1,301 w, 1,232 s, 1,168 s, 1,073 w, 1,032 m, 1,026 m, 875 w, 830 w, 748 m, 653 w, 617 w; MS: m/z (%) 433.19 (MH+ 100), 239.1 (5). Anal calcd for C~26~H~28~N~2~O~2~S (432.56): C, 72.19; H, 6.52; N, 6.48; S, 7.41%; Found: C, 72.48; H, 6.58; N, 6.34; S 7.48%.

2-((4-Ethylphenoxy)methyl)-N-(4-n-propylphenylcarbamothioyl)benzamide (1b)
--------------------------------------------------------------------------

Yield 82%; mp 139°C--140°C; ^1^H-NMR (DMSO-d6): 12.38 (br s, 1H, NH), 11.77 (br s, 1H, NH), 7.61 (br d, J = 7.4 Hz, 1H, H-7), 7.58 (m, 1H, H-4), 7.55 (td, J = 1.4 Hz, 7.4 Hz, 1H, H-5), 7.49 (d, J = 8.4 Hz, 2H, H-18, H-22), 7.46 (td, J = 1.4 Hz, 7.5 Hz, 1H, H-6), 7.21 (d, J = 8.4 Hz, 2H, H-19, H-21), 7.08 (d, J = 8.6 HZ, 2H, H-11, H-13), 6.89 (d, J = 8.6 Hz, 2H, H-10, H-14), 5.27 (s, 2H, H-8), 2.54 (q, J = 7.5 Hz, 2H, H-15), 2.49 (t, J = 7.3 Hz, 2H, H-23), 1.60 (sxt, J = 7.3 Hz, 2H, H-24), 1.12 (t, J = 7.5 Hz, 3H, H-15′), 0.90 (t, J = 7.33 Hz, H, H-25); ^13^C-NMR (DMSO-d6): 178.78 (C-16), 170.16 (C-1), 156.32 (C-9), 140.29 (Cq), 136.22 (Cq), 135.81 (Cq), 135.53 (Cq), 133.36 (Cq), 130.98 (C-5), 128.61 (C-19, C-21), 128.46 (C-7), 128.42 (C-11, C-13), 128.37 (C-4), 127.74 (C-6), 124.04 (C-18, C-22), 114.60 (C-10, C-14), 67.56 (C-8), 36.75 (C-23), 27.27 (C-15), 23.96 (C-24), 15.76 (C-15′), 13.57 (C-25); FT-IR (solid in ATR, ν cm^−1^): 3,357 w, 3,117 w, 3,038 w, 2,961 m, 2,926 m, 2,869 w, 1,669 m, 1,594 w, 1,506 vs, 1,339 m, 1,226 s, 1,175 w, 1,143 s, 1,028 m, 836 m, 734 m, 664 m, 601 w. Anal calcd for C~26~H~28~N~2~O~2~S (432.56): C, 72.19; H, 6.52; N, 6.48; S, 7.41%. Found: C, 72.37; H, 6.61; N, 6.42; S, 7.37%.

2-((4-Ethylphenoxy)methyl)-N-(4-n-butylphenylcarbamothioyl)benzamide (1c)
-------------------------------------------------------------------------

Yield 81%; mp 126°C--127°C; ^1^H-NMR (DMSO-d6): 12.38 (br s, 1H, NH), 11.77 (br s, 1H, NH), 7.61 (br d, J = 7.4 Hz, 1H, H-7), 7.59 (m, 1H, H-4), 7.56 (td, J = 1.4 Hz, 7.4 Hz, 1H, H-5), 7.49 (d, J = 8.4 Hz, 2H, H-18, H-22), 7.46 (td, J = 1.4 Hz, 7.5 Hz, 1H, H-6), 7.21 (d, J = 8.4 Hz, 2H, H-19, H-21), 7.08 (d, J = 8.6 Hz, 2H, H-11, H-13), 6.89 (d, J = 8.6 Hz, 2H, H-10, H-14), 5.27 (s, 2H, H-8), 2.58 (t, J = 7.5 HZ, 2H, H-23), 2.51 (q, J = 7.5 Hz, 2H, H-15), 1.56 (qv, J = 7.5 Hz, 2H, H-24), 1.31 (sxt, J = 7.5 Hz, 2H, H-25), 1.12 (t, J = 7.5 Hz, 3H, H-15′), 0.91 (t, J = 7.5 Hz, 3H, H-25); ^13^C-NMR (DMSO-d6): 178.76 (C-16), 170.14 (C-1), 156.27 (C-9), 140.43 (Cq), 136.15 (Cq), 135.77 (Cq), 135.45 (Cq), 133.32 (Cq), 130.91 (C-5), 128.55 (C-19, C-21), 128.42 (C-7), 128.30 (C-11, C-13), 128.29 (C-4), 127.66 (C-6), 124.01 (C-18, C-22), 114.56 (C-10, C-14), 67.50 (C-8), 34.28 (C-23), 32.98 (C-24), 27.22 (C-15), 21.66 (C-25), 15.73 (C-15′), 13.70 (C-25); FT-IR (solid in ATR, ν cm^−1^): 3,349 w, 3,233 w, 3,154 w, 3,116 w, 3,039 w, 2,958 m, 2,927 m, 2,864 w, 1,673 m, 1,593 m, 1,546 vs, 1,378 w, 1,339 s, 1,223 s, 1,176 w, 1,142 vs, 1,028 m, 955 w, 832 m, 789 w, 735 m, 668 m, 600 w. Anal calcd for C~27~H~30~N~2~O~2~S (446.60): C, 72.61; H, 6.77; N, 6.27; S, 7.18%. Found: C, 72.39; H, 6.71; N, 6.22; S, 7.18%.

2-((4-Ethylphenoxy)methyl)-N-(2,4-dimethoxyphenylcarbamothioyl) benzamide (1d)
------------------------------------------------------------------------------

Yield 71%; mp 114°C--115°C; ^1^H-NMR (DMSO-d6): 12.56 (s, 1H, NH), 11.71 (s, 1H, NH), 8.28 (d, J = 8.8 Hz, H-22), 7.61 (br d, J = 7.4 Hz, 1H, H-7), 7.58 (dd, J = 1.6 Hz, 7.4 Hz, 1H, H-4), 7.55 (td, J = 1.4 Hz, 7.4 Hz, 1H, H-5), 7.46 (td, J = 1.4 Hz, 7.8 Hz, 1H, H-6), 7.07 (d, J = 8.6 Hz, 2H, H-11--13), 6.88 (d, J = 8.6 Hz, 2H, H-10-14), 6.67 (d, J = 2.5, 1H, H-19), 6.56 (dd, J = 2.5 Hz, 8.9 Hz, 1H, H-21), 5.26 (s, 2H, H-8), 3.80 (s, 3H, H-18′ or H-20′), 3.79 (s, 3H, H-18′ or H-20′), 2.50 (q, J = 7.6 Hz, 2H, H-15), 1.11 (t, J = 7.6 Hz, 3H, H-15); ^13^C-NMR (DMSO-d6): 178.28 (C-16), 170.78 (C-1), 158.85 (C-18 or C-20), 156.91 (C-9), 152.75 (C-18 or C-20), 136.89 (Cq), 136.34 (Cq), 134.14 (Cq), 131.61 (C-5), 129.23 (C-11, C-13), 129.20 (C-4), 128.49 (C-6, C-7), 125.26 (C-22), 120.72 (C-17), 115.36 (C-10, C-14), 104.57 (C-21), 99.35 (C-19), 68.33 (C-8), 56.70 (C-18′ or C-20′), 56.09 (C-18′ or C-20′), 27.95 (C-15), 16.43 (C-15′); MS: m/z (%) 451.1 (MH+ 100), 239.1 (5); FT-IR (solid in ATR, ν cm^−1^): 3,214 m, 3,125 m, 3,031 m, 2,959 m, 1,670 m, 1,608 m, 1,548 vs, 1,503 vs, 1,465 s, 1,369 m, 1,326 s, 1,285 m, 1,229 vs, 1,160 vs, 1,120 s, 1,069 w, 913 w, 856 w, 827 m, 788 m, 721 m, 668 w, 629 w. Anal calcd for C~25~H~26~N~2~O~4~S (450.55): C, 66.65; H, 5.82; N, 6.22; S, 7.12%. Found: C, 66.34; H, 5.71; N, 6.24; S, 7.19%.

2-((4-Ethylphenoxy)methyl)-N-(2,4-dibromophenylcarbamothioyl)benzamide (1e)
---------------------------------------------------------------------------

Yield 76%; mp 153°C--154°C; ^1^H-NMR (DMSO-d6): 12.36 (br s, 1H, NH), 12.09 (br s, 1H, NH), 7.95 (d, J = 2.4 Hz, 1H, H-19), 7.90 (d, J = 8.6 Hz, 1H, H-22), 7.63 (br d, J = 7.4 Hz, 1H, H-7), 7.62 (dd, J = 2.4 Hz, 8.6 Hz, 1H, H-21), 7.60 (m, 1H, H-4), 7.58 (td, J = 1.4 Hz, 7.4 Hz, 1H, H-5), 7.47 (td, J = 1.4 Hz, 7.5 Hz, 1H, H-6), 7.08 (d, J = 8.6 Hz, 2H, H-11, H-13), 6.89 (d, J = 8.6 Hz, 2H, H-10, H-14), 5.27 (s, 2H, H-8), 2.50 (q, J = 7.5 Hz, 2H, H-15), 1.13 (t, J = 7.5 Hz, 3H, H-15′); ^13^C-NMR (DMSO-d6): 180.16 (C-16), 170.24 (C-1), 156.22 (C-9), 136.45 (Cq), 136.16 (Cq), 135.79 (Cq), 134.46 (C-19), 133.17 (Cq), 131.08 (C-5), 130.67 (C-21), 129.89 (C-22), 128.55 (C-1 1, C-13, C-4, C-7), 127.78 (C-6), 120.32 (C-20), 119.70 (C-18), 114.55 (C-10, C-14), 67.49 (C-8), 27.25 (C-15), 15.79 (C-15′); FT-IR (solid in ATR, ν cm^−1^): 3,260 w, 3,082 w, 2,961 w, 2,918 w, 2,867 w, 1,677 m, 1,615 w, 1,559 m, 1,512 vs, 1,377 m, 1,311 m, 1,238 s, 1,161 s, 1,076 w, 1,041 m, 940 w, 860 w, 765 w, 735 w, 675 m, 605 w; MS: m/z (%) 548.9 (MH+ 100), 467 (26), 270.2 (25), 239.1 (5). Anal calcd for C~23~H~20~Br~2~N~2~O~2~S (548.29): C, 50.38; H, 3.68; N, 5.11; S, 5.85%. Found: C, 50.15; H, 3.61; N, 5.02; S, 5.89%.

2-((4-Ethylphenoxy)methyl)-N-(2,5-dibromophenylcarbamothioyl)benzamide (1f)
---------------------------------------------------------------------------

Yield 89%; mp 128°C--129°C; ^1^H-NMR (DMSO-d6): 12.42 (br s, 1H, NH), 12.12 (br s, 1H, NH), 8.06 (d, J = 2.4 Hz,1H, H-22), 7.66 (d, J = 8.6 Hz, 1H, H-19), 7.63 (br d, J = 7.4 Hz, 1H, H-7), 7.60 (m, 1H, H-4), 7.58 (td, J = 1.4 Hz, 7.4 Hz, 1H, H-5), 7.47 (td, J = 1.4 Hz, 7.5 Hz, 1H, H-6), 7.43 (dd, J = 2.4 Hz, 8.6 Hz, 1H, H-20), 7.08 (d, J = 8.6 Hz, 2H, H-11, H-13), 6.89 (d, J = 8.6 Hz, 2H, H-10, H-14), 5.26 (s, 2H, H-8), 2.50 (q, J = 7.52 Hz, H, 2H-15), 1.13 (t, J = 7.5 Hz, 3H, H-15′); ^13^C-NMR (DMSO-d6): 180.14 (C-16), 170.28 (C-1), 156.22 (C-9), 138.26 (Cq), 136.14 (Cq), 135.71 (Cq), 134.13 (C-19), 133.25 (Cq), 131.03 (C-5), 131.00 (C-20), 130.67 (C-22), 128.55 (C-7), 128.51 (C-11, C-13), 128.46 (C-4), 127.61 (C-6), 119.64 (C-21), 118.34 (C-18), 114.49 (C-10, C-14), 67.53 (C-8), 27.24 (C-15), 15.74 (C-15′); FT-IR (solid in ATR, ν cm^−1^): 3,240 m, 2,964 w, 1,674 m, 1,610 w, 1,569 m, 1,516 vs, 1,397 w, 1,313 m, 1,243 s, 1,159 s, 1,077 w, 1,044 m, 875 w, 823 w, 795 w, 755 w, 706 m, 611 w; MS: m/z (%) 548.9 (MH+ 100), 467 (14), 239.1 (5). Anal calcd for C~23~H~20~Br~2~N~2~O~2~S (548.29): C, 50.38; H, 3.68; N, 5.11; S, 5.85%. Found: C, 50.21; H, 3.59; N, 5.12; S, 5.81%.

2-((4-Ethylphenoxy)methyl)-N-(3-trifluor omethylphenylcarbamothioyl)benzamide (1g)
----------------------------------------------------------------------------------

Yield 73%; mp 119°C--120°C; ^1^H-NMR (DMSO-d6): 12.48 (br s, 1H, NH), 11.96 (br s, 1H, NH), 8.07 (bs, 1H, H-18), 7.80 (dq, J = 7.1 Hz, 1H, H-22, 4 J (H18, 20-H22) = 1.6 Hz), 7.67-7.60 (m, 4H, H-4, H-7, H-20, H-21), 7.57 (td, J = 1.4 Hz, 7.4 Hz, 1H, H-5), 7.48 (td, J = 1.4 Hz, 7.5 Hz, 1H, H-6), 7.09 (d, J = 8.6 Hz, 2H, H-11, H-13), 6.90 (d, J = 8.6 Hz, 2H, H-10, H-14), 5.27 (s, 2H, H-8), 2.51 (q, J = 7.5 Hz, 2H, H-15), 1.11 (t, J = 7.5 Hz, 3H, H-15′); ^13^C-NMR (DMSO-d6): 179.58 (C-16), 170.03 (C-1), 156.27 (C-9), 138.68 (Cq), 136.16 (Cq), 135.78 (Cq), 133.26 (Cq), 130.96 (C-5), 129.73 (C-22), 129.12 (q, C-19, 2J (3F-C19) = 31.9 Hz), 128.60 (C-21), 128.49 (C-11, C-13), 128.37 (C-7), 128.30 (C-4), 127.69 (C-6), 123.82 (q, CF3, J (3F-C) = 271.0 Hz), 122.70 (q, C-20, 3J (3F-C20) = 3.3 Hz), 121.00 (q, C-18, 3J (3F-C18) = 4.0 Hz), 114.51 (C-10, C-14), 67.51 (C-8), 27.17 (C-15), 15.63 (C-15′); ^19^F-NMR (DMSO-d6): −56.92 (3F); FT-IR (solid in ATR ν cm^−1^): 3,178 s, 3,030 m, 2,971 s, 2,934 m, 2,877 m, 1,693 s, 1,600 m, 1,555 vs, 1,531 vs, 1,513 vs, 1,451 s, 1,397 m, 1,331 s, 1,309 s, 1,282 m, 1,248 vs, 1,230 s, 1,164 vs, 1,112 vs, 1,075 s, 1,033 m, 966 w, 951 w, 889 w, 859 w, 827 m, 795 m, 761 m, 737 s, 692 m, 680 m, 660 w, 646 m, 623 w, 572 w; MS: m/z (%) 459.1 (MH+ 100), 425.1 (7), 239.1 (7). Anal calcd for C~24~H~21~F~3~N~2~O~2~S (458.49): C, 62.87; H, 4.62; N, 6.11; S, 6.99%. Found: C, 62.65; H, 4.37; N, 6.12; S, 6.93%.

2-((4-Ethylphenoxy)methyl)-N-(3-nitrophenylcarbamothioyl)benzamide (1h)
-----------------------------------------------------------------------

Yield 72%; mp 148°C--149°C; ^1^H-NMR (DMSO-d6): 12.54 (s, 1H, NH), 12.01 (br s, 1H, NH), 8.65 (t, J = 2.3 Hz, 1H, H-18), 8.12 (ddd, J = 1.0 Hz, 2.3 Hz, 8.2 Hz, 1H, H-20), 7.93 (ddd, J = 1.0 Hz, 2.3 Hz, 8.2 Hz, 1H, H-22), 7.69 (t, J = 8.2 Hz, 1H, H-21), 7.61 (br d, J = 7.4 Hz, 1H, H-7), 7.58 (dd, J = 1.6 Hz, 7.4 Hz, 1H, H-4), 7.55 (td, J = 1.4 Hz, 7.4 Hz, 1H, H-5), 7.46 (td, J = 1.4 Hz, 7.8 Hz, 1H, H-6), 7.06 (d, J = 8.6 Hz, 2H, H-11, H-13), 6.88 (d, J = 8.6 Hz, 2H, H-10-14), 5.28 (s, 2H, H-8), 2.51 (q, J = 7.6 Hz, 2H, H-15), 1.12 (t, J = 7.6, 3H, H-15); ^13^C-NMR (DMSO-d6): 179.64 (C-16), 169.99 (C-1), 156.22 (C-9), 147.43 (C-19), 139.03 (Cq), 136.19 (Cq), 135.79 (Cq), 133.19 (Cq), 131.05 (C-21), 130.01 (C-5), 129.87 (C-22), 128.51 (C-11, C-13), 128.37 (C-4), 128.32 (C-7), 127.71 (C-6), 120.78 (C-20), 119.00 (C-18), 114.49 (C-10, C-14), 67.48 (C-8), 27.16 (C-15), 15.64 (C-15′); FT-IR (solid in ATR, ν cm^−1^): 3,156 m, 2,966 w, 2,923 w, 2,859 w, 1,678 m, 1,606 w, 1,509 vs, 1,384 w, 1,344 m, 1,313 m, 1,232 m, 1,171 m, 1,070 w, 1,033 m, 898 w, 822 w, 766 w, 737 m, 695 m, 601 w, 538 w; MS: m/z (%) 436.1 (MH+ 100), 239.1 (9). Anal calcd for C~23~H~21~N~3~O~4~S (435.51): C, 63.43; H, 4.86; N, 9.65; S, 7.36%. Found: C, 63.61; H, 4.77; N, 9.58; S, 7.34%.
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![Synthetic pathway for the new *N*-phenylcarbamothioylbenzamides 1a--h.](dddt-7-883Fig1){#f1-dddt-7-883}

![Percent inhibition of carrageenan paw edema for *N*-phenylcarbamothioylbenzamides 1a--h in mice.^a^\
**Notes:** ^a^Doses administered: indomethacin and test compounds 1a--h (0.028 mmol). Percentage of inhibition of edema expressed as means of five replicates ± standard error of the mean. \*Significantly statistically different from IND group (*P* = 0.049 for 1a, 0.0015 for 1d, and 0.033 for 1f); \*\*significantly statistically different from IND group and groups treated with 1a (*P* = 0.0014 for 1e and 0.0022 for 1h), 1b, 1c, and 1d (*P* = 0.031 for 1e), 1f (*P* = 0.026 for 1e), and 1g (*P* = 0.0011 for 1h); ^\#^no activity observed.\
**Abbreviations:** CON, placebo control; IND, positive control.](dddt-7-883Fig2){#f2-dddt-7-883}

![Inhibition of prostaglandin E~2~ (PGE~2~) by test compounds 1a, 1e, and 1h.\
**Notes:** Percent inhibition of PGE~2~ synthesis expressed as means of five replicates ± standard error of the mean. Doses administered: indomethacin and test compounds 1a, 1e, and 1h (0.028 mmol/kg). \*significantly statistically different from CON group (*P* \< 0.001); ^\#^significantly statistically different from IND group (*P* = 0.040) and 1a (*P* \< 0.001).\
**Abbreviations:** CON, placebo control; IND, positive control.](dddt-7-883Fig3){#f3-dddt-7-883}

###### 

Effect of indomethacin and compounds 1a, 1e, and 1h on ulcerogenic properties

  Compound   Ulcer incidence, number/group   Ulcer index, mean ± SEM (mm)                                                                       \% incidence
  ---------- ------------------------------- -------------------------------------------------------------------------------------------------- --------------
  IND        4/5                             0.60 ± 0.11                                                                                        80
  1a         4/5                             0.50 ± 0.16                                                                                        80
  1e         1/5                             0.20 ± 0.02[a](#tfn1-dddt-7-883){ref-type="table-fn"},[b](#tfn2-dddt-7-883){ref-type="table-fn"}   20
  1h         1/5                             0.40 ± 0.12                                                                                        20

**Notes:**

Significantly statistically different from IND values (*P* = 0.001);

significantly statistically different from 1a (*P* = 0.009).

**Abbreviations:** IND, indomethacin; SEM, standard error of the mean.
